Bausch Health Companies Investor Conference Presentation Deck slide image

Bausch Health Companies Investor Conference Presentation Deck

18 Reconciliation of Reported Revenue to Organic Revenue ¹,2 and Organic Revenue Growth ¹,2 ($M) (Quarter-to-Date)4 Bauch +Lomb 4 Global Vision Care Global Surgical Global Consumerª Global Ophtho Rx4 Total Bausch + Lomb Bausch Pharma5 Salix Salix International Rx4 International Rx4 Ortho Dermatologics4 Ortho Dermatologics 4 Global Solta Total Ortho Dermatologics Diversified Products Neurology & Otherª Generics Dentistry Total Diversified Products Total Bausch Pharm a revenues 5 Total Bausch Health revenues BAUSCH- Health Revenue as Reported 226 173 379 171 949 527 271 66 74 140 151 48 25 224 1,162 Calculation of Organic Revenue for the Three Months Ended September 30, 2021 September 30, 2020 Changes in Exchange Rates ³ $ 2,111 $ (1) (4) (3) (2) (10) (2) (2) (19) $ Organic Revenue (Non- GAAP) ¹,2 225 169 376 169 939 527 264 66 72 138 151 48 25 224 1,153 2,092 Revenue as Reported 214 151 351 200 916 496 308 70 73 143 200 56 19 275 1,222 $ 2,138 Divestitures and Discontinuations $ CE (4) (42) (42) (46) $ Organic Revenue (Non- GAAP) ¹,2 213 150 350 199 912 496 266 70 73 143 200 56 19 275 1,180 Change in Organic Revenue Amount 2,092 $ 12 19 26 (30) 27 31 (49) (8) 6 (51) Pct. (27) 6% 13% 7% -15% 3% 6% (4) -6% (1) -1% (5) -3% -1% -25% -14% 32% -19% -2% 0% 1. See Slide 2 and this Appendix for further non-GAAP information 2 Organic growth/change, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations. 3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period. 4. See footnote 3 at slide 6 for further details regarding the realigned segment reporting structure and the conformed prior period presentation. 5. Bausch Pharma revenues, a non-GAAP metric, are determined by subtracting Bausch+Lomb segment revenues for the applicable period from total Bausch Health revenues for the applicable period.
View entire presentation